GYRE Gyre Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: GYRE

Price (delayed)

$15.14

Market cap

$1.29B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.41

Enterprise value

$1.26B

catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. we used a scientific approach focused on protease-based therapeutic ...

Highlights
GYRE's EPS has surged by 92% since the previous quarter
Gyre Therapeutics's debt has decreased by 33% YoY
The net income has plunged by 176% from the previous quarter
The company's equity has shrunk by 137% YoY
Sector: Healthcare
Industry: Biotechnology
Peers: OMER OMGA

Key stats

What are the main financial stats of GYRE
Market
Shares outstanding
85.42M
Market cap
$1.29B
Enterprise value
$1.26B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
8.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.11
Earnings
Revenue
$113.45M
EBIT
-$84.42M
EBITDA
-$82.99M
Free cash flow
$18.04M
Per share
EPS
-$1.41
Free cash flow per share
$0.27
Book value per share
-$6.25
Revenue per share
$1.72
TBVPS
$1.74
Balance sheet
Total assets
$116.54M
Total liabilities
$38.07M
Debt
$409,000
Equity
-$15.83M
Working capital
$37.17M
Liquidity
Debt to equity
-0.03
Current ratio
2.85
Quick ratio
2.75
Net debt/EBITDA
0.4
Margins
EBITDA margin
-73.2%
Gross margin
95.9%
Net margin
-81.9%
Operating margin
-59.3%
Efficiency
Return on assets
-235.8%
Return on equity
N/A
Return on invested capital
-455.5%
Return on capital employed
-87.5%
Return on sales
-74.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GYRE stock price

How has the Gyre Therapeutics stock price performed over time
Intraday
7.38%
1 week
-11.51%
1 month
-11.77%
1 year
378.13%
YTD
-41.07%
QTD
-13.39%

Financial performance

How have Gyre Therapeutics's revenue and profit performed over time
Revenue
$113.45M
Gross profit
$108.81M
Operating income
-$67.23M
Net income
-$92.93M
Gross margin
95.9%
Net margin
-81.9%
The net income has plunged by 176% from the previous quarter
GYRE's operating income has dropped by 154% since the previous quarter
Gyre Therapeutics's net margin has shrunk by 147% QoQ
The company's operating margin has shrunk by 127% QoQ

Growth

What is Gyre Therapeutics's growth rate over time

Valuation

What is Gyre Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
8.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.11
GYRE's EPS has surged by 92% since the previous quarter
The company's equity has shrunk by 137% YoY
The stock's price to sales (P/S) is 131% more than its last 4 quarters average of 3.8 and 9% more than its 5-year quarterly average of 8.1
GYRE's revenue is up by 12% since the previous quarter and by 11% year-on-year

Efficiency

How efficient is Gyre Therapeutics business performance
GYRE's return on sales has dropped by 164% since the previous quarter
GYRE's ROIC has plunged by 133% from the previous quarter
Gyre Therapeutics's ROA has plunged by 120% from the previous quarter

Dividends

What is GYRE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GYRE.

Financial health

How did Gyre Therapeutics financials performed over time
GYRE's quick ratio is down by 39% since the previous quarter and by 21% year-on-year
GYRE's total assets is up by 38% year-on-year
Gyre Therapeutics's debt is 103% higher than its equity
The company's equity has shrunk by 137% YoY
Gyre Therapeutics's debt has decreased by 33% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.